Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.52 -4.6%	$1.02	$0.61 ▼ $5.94	$22.18M	0.08	3.93 million shs	6.32 million shs
NXTC NextCure	$5.19 -1.0%	$5.20	$2.69 ▼ $19.20	$13.90M	1.25	52,889 shs	11,082 shs
ONVO Organovo		$3.94	$1.56 ▼ $21.96	$3.47M	1.13	617,505 shs	243,634 shs
PRPH ProPhase Labs	$0.35 +5.2%	$0.37	$0.22 ▼ $3.00	$14.37M	-0.48	6.68 million shs	984,826 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	+11.19%	+82.97%	+41.96%	+78.33%	-67.92%
NXTC NextCure	+0.38%	+1.67%	-5.42%	-12.03%	-72.36%
ONVO Organovo	0.00%	0.00%	0.00%	0.00%	-72.45%
PRPH ProPhase Labs	-4.17%	-0.27%	-25.92%	-9.89%	-86.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLR Allarity Therapeutics	2.9753 of 5 stars	3.5	5.0	0.0	0.0	3.0	0.0	0.6
NXTC NextCure	4.4359 of 5 stars	3.3	3.0	0.0	4.3	3.3	1.7	1.3
ONVO Organovo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRPH ProPhase Labs	1.3098 of 5 stars	0.0	5.0	0.0	0.0	3.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	3.00	Buy	$9.00	493.28% Upside
NXTC NextCure	2.67	Moderate Buy	$25.50	391.71% Upside
ONVO Organovo	0.00	N/A	N/A	N/A
PRPH ProPhase Labs	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ONVO, ALLR, NXTC, and PRPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2025	ALLR Allarity Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
7/15/2025	NXTC NextCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$36.00 ➝ $15.00
7/8/2025	NXTC NextCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	$0.83 per share	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	$11.82 per share	N/A
ONVO Organovo	$122K	0.00	N/A	N/A	$0.02 per share	0.00
PRPH ProPhase Labs	$6.77M	2.12	N/A	N/A	$0.28 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$24.51M	N/A	0.00	N/A	N/A	N/A	-173.31%	-102.57%	11/13/2025 (Estimated)
NXTC NextCure	-$55.65M	-$25.82	N/A	N/A	N/A	N/A	-106.62%	-85.20%	11/6/2025 (Estimated)
ONVO Organovo	-$14.67M	-$10.20	N/A	N/A	N/A	-10,151.64%	-346.26%	-187.53%	N/A
PRPH ProPhase Labs	-$53.36M	-$1.26	N/A	N/A	N/A	N/A	-262.42%	-76.48%	11/12/2025 (Estimated)

Latest ONVO, ALLR, NXTC, and PRPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	ALLR Allarity Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	N/A	N/A
8/13/2025	Q2 2025	PRPH ProPhase Labs	-$0.15	-$0.11	+$0.04	-$0.11	$3.55 million	$1.25 million
8/7/2025	Q2 2025	NXTC NextCure	-$4.62	-$11.29	-$6.67	-$11.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
ONVO Organovo	N/A	N/A	N/A	N/A	N/A
PRPH ProPhase Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	2.31	2.31
NXTC NextCure	N/A	3.71	3.71
ONVO Organovo	N/A	0.72	1.72
PRPH ProPhase Labs	0.20	0.96	0.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
NXTC NextCure	42.65%
ONVO Organovo	8.23%
PRPH ProPhase Labs	9.45%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.08%
NXTC NextCure	17.90%
ONVO Organovo	3.72%
PRPH ProPhase Labs	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	14.62 million	14.61 million	Not Optionable
NXTC NextCure	90	2.68 million	2.20 million	Optionable
ONVO Organovo	20	1.70 million	14.79 million	Optionable
PRPH ProPhase Labs	130	41.54 million	37.55 million	Optionable

ONVO, ALLR, NXTC, and PRPH Headlines

Recent News About These Companies

ProPhase Labs, Inc. (PRPH) Q2 2025 Earnings Call Transcript

August 20, 2025 | seekingalpha.com

ProPhase Labs files definitive proxy statement for special meeting

August 20, 2025 | msn.com

ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders

August 19, 2025 | globenewswire.com

ProPhase Labs Inc (PRPH) Q2 2025 Earnings Call Highlights: Strategic Moves and Future Prospects

August 15, 2025 | finance.yahoo.com

ProPhase Labs Reports Turnaround and Strategic Growth

August 14, 2025 | msn.com

ProPhase Labs Posts Narrower Q2 Loss

August 13, 2025 | aol.comA

ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025

August 13, 2025 | globenewswire.com

ProPhase Labs stock soars after securing patent for esophageal disease test

August 12, 2025 | investing.com

Earnings Preview For ProPhase Labs

August 12, 2025 | benzinga.com

ProPhase Labs Shares Surge 38% Following Patent Approval for Esophageal Disease Test

August 12, 2025 | msn.com

Why Is ProPhase Labs Stock (PRPH) Up 25% Today?

August 12, 2025 | msn.com

ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment

August 12, 2025 | globenewswire.com

ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025

August 11, 2025 | globenewswire.com

ProPhase Labs Appoints New Fractional CFO

August 6, 2025 | tipranks.com $https://www.tipranks.com/news/company-announcements/prophase-labs-appoints-new-fractional-cfo?utm_source=marketbeat.com&utm_medium=referral$

ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement

July 29, 2025 | globenewswire.com

ProPhase Labs announces closing of $3M senior secured convertible notes

July 25, 2025 | msn.com

ProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing

July 23, 2025 | globenewswire.com

ProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury Initiative

July 21, 2025 | globenewswire.com

ProPhase Labs Regains Nasdaq Compliance with New Appointment

July 1, 2025 | tipranks.com

ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule - Morningstar

June 27, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONVO, ALLR, NXTC, and PRPH Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$1.52 -0.07 (-4.59%)

Closing price 03:59 PM Eastern

Extended Trading

$1.48 -0.04 (-2.57%)

As of 04:04 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

NextCure NASDAQ:NXTC

$5.17 -0.07 (-1.34%)

As of 04:00 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

ProPhase Labs NASDAQ:PRPH

$0.35 +0.02 (+5.20%)

Closing price 03:58 PM Eastern

Extended Trading

$0.34 0.00 (-0.58%)

As of 04:04 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time